alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › anti-amyloid-treatment

anti-amyloid-treatment

4 studies tagged anti-amyloid-treatment, dated 2021-08-17 to 2026-10-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Residualized occipital amyloid burden and plasma biomarker profiles in relation to ARIA-E during anti-amyloid treatment 2026-10-09
  2. Eligibility for anti-amyloid treatment in a multiethnic community-based study 2026-04-01
  3. Anti-amyloid treatments: Why we think they are worth it 2025-01-01

Studies

4 studies carry this tag.

Date range

2021 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 3
  • Alzheimer's & dementia (New York, N. Y.) 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Residualized occipital amyloid burden and plasma biomarker profiles in relation to ARIA-E during anti-amyloid treatment

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-10-09 Treatments

    Disproportionate occipital amyloid burden may identify a biologically vulnerable subgroup requiring validation in larger cohorts.

  2. Eligibility for anti-amyloid treatment in a multiethnic community-based study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-04-01 Treatments

    Few individuals in this community-based, multiethnic cohort met eligibility for anti-amyloid therapy, highlighting limited real-world applicability of current AURs.

  3. Anti-amyloid treatments: Why we think they are worth it

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-01-01 Treatments

    Years of experience watching our patients progressively decline and die from complications of Alzheimer's disease (AD) has strongly motivated us to provide newly approved anti-amyloid treatments to appropriate patients.

  4. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2021-08-17 Treatments

    The results of this small pilot study support the use of retinal fundus imaging for detecting amyloid deposition that is correlated with brain amyloid PET SUVr.

All topic tags with their study counts